|
Nasdaq:MEDI
NASDAQ100
MedImmune
Inc. is a biotechnology company with five products on the market and a
diverse product pipeline. The Company is focused on using advances in immunology
and other biological sciences to develop new products that address significantly
unmet medical needs in areas of infectious disease and immune regulation.
|
MedImmune
Announces Preliminary Results for 2007 First Quarter
Company
Invites Investors to Participate in First-Quarter 2007 Earnings Conference
Call on May 3, 2007
GAITHERSBURG,
Md., April 9, 2007 /PRNewswire-FirstCall via COMTEX News Network/ -- MedImmune,
Inc. (Nasdaq: MEDI) announced today that it anticipates its first-quarter
diluted earnings per share (EPS), excluding share-based compensation expense,
to be in the range of $0.62 to $0.67, as compared to $0.23 in diluted EPS
in the 2006 first quarter, excluding share-based compensation. This nearly
three-fold increase in expected EPS is due to an estimated 11-to-12 percent
increase in total revenues and a greater than two-fold increase in net
income margin. The company also stated that for the 2007 first quarter,
it expects domestic and worldwide net sales growth of approximately 9-to-10
percent for Synagis(R) (palivizumab) over the same quarter in 2006.
MedImmune
anticipates reporting its final 2007 first-quarter financial results on
May 3, 2007 before the opening of the U.S. financial markets. This allows
MedImmune to report royalties and milestones earned on its HPV vaccine
technology in the same quarter as the related vaccine sales are reported
by Merck and GlaxoSmithKline. The company is also planning to host a conference
call and live audio webcast at 8:00 a.m. eastern time following the announcement.
During the conference call, MedImmune's management will discuss the financial
results and other business.
The
press release and the live webcast can be accessed by going to the Investor
Relations section of the MedImmune website at www.medimmune.com. An archived
version of the call will be available at the same address for one week
after the live webcast.
MedImmune
strives to provide better medicines to patients, new medical options for
physicians, rewarding careers to employees, and increased value to shareholders.
Dedicated to advancing science and medicine to help people live better
lives, the company is focused on the areas of infectious disease, cancer
and inflammatory diseases. With more than 2,500 employees worldwide, MedImmune
is headquartered in Maryland. For more information, visit the company's
website at www.medimmune.com.
MedImmune
Further Expands its Commercial Organization Expertise With Appointment
of Two Additional Vice Presidents
GAITHERSBURG,
Md., Feb. 20 /PRNewswire-FirstCall/ -- MedImmune, Inc. (Nasdaq: MEDI) today
announced that it has added two senior leaders to its commercial management
organization. The new executive appointments are Jamie Harrell, vice president,
infectious disease marketing, and Mark Stanton, vice president, managed
markets. The addition of Mr. Harrell and Mr. Stanton builds on MedImmune's
commercial leadership expansion, which included several senior appointments
in 2006.
"Jamie
and Mark bring a depth of experience and knowledge that we expect to be
critically instrumental in helping us achieve our long-term growth goals
for our respiratory syncytial virus (RSV) franchise," said David M. Mott,
chief executive officer and president. "They join a dedicated management
team, passionate about creating value for shareholders, new medical options
for patients and healthcare providers, and rewarding careers for employees."
MedImmune
Reports Financial Results For 2006
Fourth
Quarter and Full Year Earnings for 2006 Up Dramatically Over 2005 -
Fourth
Quarter Total Revenues Increase 7 Percent -
Company
Confirms Significant Growth Objectives for 2007 -
Recent
Highlights
Fourth
quarter 2006 adjusted earnings were $0.64 per diluted share vs. adjusted
earnings of $0.08 per diluted share for the 2005 quarter
Full
year adjusted earnings in 2006 were $0.30 per diluted share vs. adjusted
earnings of $0.13 per diluted share in 2005
Reported
U.S. sales of Synagis(R) increased 6 percent for both 2006 fourth quarter
and first half of 2006-2007 RSV season
Sales
of FluMist(R) increased 71 percent for full year 2006 and 128 percent for
the fourth quarter
Other
Revenues increased 130 percent in the 2006 fourth quarter and 143 percent
for full year 2006
Refrigerated
FluMist approved in United States
First
licensing of reverse genetics technology
Numax(R)
achieved primary endpoint in comparative Phase 3 trial versus Synagis
Inflammatory
disease pipeline expanded with Phase 1 monoclonal antibody targeting IL-5
for treatment of asthma
School-based
vaccination program with FluMist published in December 2006 issue of The
New England Journal of Medicine
CytoGam(R)
sold to ZLB Behring AG
GAITHERSBURG,
Md., Feb. 7 /PRNewswire-FirstCall/ -- MedImmune, Inc. (Nasdaq: MEDI) announced
today that total revenue for 2006 grew to approximately $1.3 billion from
approximately $1.2 billion in 2005. MedImmune's fourth quarter total revenues
increased 7 percent to $529 million driven by gains in Synagis (palivizumab),
FluMist (Influenza Vaccine Virus Live, Intranasal) and Other Revenue. In
the 2005 fourth quarter, total revenues were $492 million.
MedImmune
also announced today that it had exceeded its earnings guidance for 2006
by reporting net earnings of $75 million, or $0.30 per diluted share, excluding
share-based compensation expense. Including share-based compensation, MedImmune's
net earnings for 2006 were $49 million, or $0.20 per diluted share, as
calculated in accordance with generally accepted accounting principles
(GAAP). In 2005, when share-based compensation was not included in results
of operations, MedImmune's GAAP net loss was $17 million, or $0.07 per
share. Adjusted earnings for 2005 of $31 million, or $0.13 per diluted
share, exclude the impact of acquired in-process research and development
(IPR&D) associated with the 2005 acquisition of Cellective Therapeutics,
Inc. and certain transition costs.
For
the 2006 fourth quarter, MedImmune's net earnings were $155 million, or
$0.64 per diluted share, excluding share-based compensation. Including
share-based compensation, MedImmune's GAAP net earnings in the 2006 fourth
quarter were $121 million, or $0.50 per diluted share. This compares to
a GAAP net loss of $22 million, or $0.09 per share in the 2005 fourth quarter.
Adjusted earnings for the fourth quarter of 2005 were $21 million, or $0.08
per diluted share.
|
